Trials / Completed
CompletedNCT02507544
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- TaiRx, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines. The objectives of this study are to determine the safety profile of TRX-818 including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) and determine the recommended dose and regimen(s) to initiate Phase 2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRX-818 capsules |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2017-04-29
- Completion
- 2019-05-20
- First posted
- 2015-07-24
- Last updated
- 2020-05-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02507544. Inclusion in this directory is not an endorsement.